| Ident. | Authors (with country if any) | Title |
|---|
| 000038 |
D. M. Johnstone [Australie] ; N. El Massri [Australie] ; C. Moro [France] ; S. Spana [Australie] ; X. S. Wang [Australie] ; N. Torres [France] ; C. Chabrol [France] ; X. De Jaeger [France] ; F. Reinhart [France] ; S. Purushothuman [Australie] ; A.-L. Benabid [France] ; J. Stone [Australie] ; J. Mitrofanis [Australie] | INDIRECT APPLICATION OF NEAR INFRARED LIGHT INDUCES NEUROPROTECTION IN A MOUSE MODEL OF PARKINSONISM - AN ABSCOPAL NEUROPROTECTIVE EFFECT |
| 000193 |
J. Bove [Espagne] ; C. Perier [Espagne] | NEUROTOXIN-BASED MODELS OF PARKINSON'S DISEASE |
| 000236 |
H. Iderberg [Suède] ; V. Francardo [Suède] ; E. Y. Pioll [Royaume-Uni] | ANIMAL MODELS OF L-DOPA-INDUCED DYSKINESIA: AN UPDATE ON THE CURRENT OPTIONS |
| 000300 |
Rui D. S. Prediger [Brésil] ; Aderbal S. Jr Aguiar [Brésil] ; Eduardo L. G. Moreira [Brésil] ; Filipe C. Matheus [Brésil] ; Adalberto A. Castro [Brésil] ; Roger Walz [Brésil] ; Andreza F. De Bem [Brésil] ; Alexandra Latini [Brésil] ; Carla I. Tasca [Brésil] ; Marcelo Farina [Brésil] ; Rita Raisman-Vozari [France] | The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease |
| 000359 |
Masahiro Shin [France] ; Caroline Jan [France] ; Carine Jacquard [France] ; Bechir Jarraya [France] ; Jacques Callebert [France] ; Jean-Marie Launay [France] ; Philippe Hantraye [France] ; Philippe Remy [France] ; Stephane Palfi [France] ; Emmanuel Brouillet [France] | Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration |
| 000737 |
Dieter Scheller [Allemagne] ; Christine Stichel-Gunkel [Allemagne] ; Hermann Lübbert [Allemagne] ; Gregory Porras [France] ; Paula Ravenscroft [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France, Royaume-Uni] | Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease |
| 000843 |
Charlotte Laloux [France] ; Philippe Derambure [France] ; Jean-Marie Jacquesson [France] ; Régis Bordet [France] ; Alain Destée [France] ; Christelle Monaca [France] | The effects of serotoninergic, noradrenergic, cholinergic and dopaminergic drugs on vigilance states in MPTP-treated mice |
| 000880 |
Alexandre Kreisler [France] ; Patrick Gele [France] ; Jean-Francois Wiart [France] ; Michel Lhermitte [France] ; Alain Destke [France] ; Régis Bordet [France] | Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease : Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not |
| 000B14 |
Yan-Qin Shen [République populaire de Chine, France] ; Guillaume Hebert [France] ; Yun Su [France] ; Elizabeth Moze [France] ; Pierre J. Neveu [France] ; Kang-Sheng Li [République populaire de Chine] | In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization |
| 000C34 |
Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque |
| 000C46 |
Carlos Barcia [Espagne] ; Angel Sanchez Bahillo [Espagne] ; Emiliano Fernandez-Villalba [Espagne] ; Victor Bautista [Espagne] ; Maximo Poza Y. Poza [Espagne] ; Andrés Fernandez-Barreiro [Espagne] ; Etienne C. Hirsch [France] ; Maria-Trinidad Herrero [Espagne] | Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure |
| 001043 |
Karine Parain [France] ; Véronique Marchand [France] ; Bernard Dumery [France] ; Etienne Hirsch [France] | Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice |
| 001094 |
Stéphanie Barc [France] ; Guylène Page [France] ; Bernard Fauconneau [France] ; Laurence Barrier [France] ; Francois Huguet [France] | A new in vitro approach for investigating the MPTP effect on DA uptake |
| 001221 |
T. Boraud [France] ; E. Bezard [France] ; J. M. Stutzmann [France] ; B. Bioulac [France] ; C. E. Gross [France] | Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey |
| 001328 |
C. Fillebeen [France] ; V. Mitchell [France] ; D. Dexter [Royaume-Uni] ; M. Benaissa [France] ; J.-C. Beauvillain [France] ; G. Spik [France] ; A. Pierce [France] | Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment |
| 001331 |
R. J. Ferrante [États-Unis] ; P. Hantraye [France] ; E. Brouillet [France] ; M. F. Beal [États-Unis] | Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase |
| 001372 |
J. A. Aguirre [Espagne] ; A. Cintra [Suède] ; J. Hillion [Suède] ; J. A. Narvaez [Espagne] ; A. Jansson [Suède] ; T. Antonelli [Italie] ; L. Ferraro [Italie] ; F. A. Rambert [France] ; K. Fuxe [Suède] | A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse |
| 001425 |
H. Bergman [Israël] ; A. Raz [Israël] ; A. Feingold [Israël] ; A. Nini [Israël] ; I. Nelken [Israël] ; D. Hansel [France] ; H. Ben-Pazi [Israël] ; A. Reches [Israël] | Physiology of MPTP tremor |
| 001452 |
T. Boraud [France] ; E. Bezard [France] ; D. Guehl [France] ; B. Bioulac [France] ; C. Gross [France] | Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey |
| 001467 |
N. Aubin [France] ; O. Curet [France] ; A. Deffois [France] ; C. Carter [France] | Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice |
| 001548 |
A. Boireau [France] ; F. Bordier [France] ; P. Dubedat [France] ; C. Peny [France] ; A. Imperato [France] | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice |
| 001558 |
E. Bezard [France] ; T. Boraud [France] ; B. Bioulac [France] ; C. E. Gross [France] | Presymptomatic revelation of experimental Parkinsonism |
| 001569 |
E. Bezard [France] ; S. Dovero [France] ; B. Bioulac [France] ; C. E. Gross [France] | Kinetics of nigral degeneration in a chronic model of MPTP-treated mice |
| 001601 |
E. Bezard [France] ; C. Imbert [France] ; X. Deloire [France] ; B. Bioulac [France] ; C. E. Gross [France] | A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey |
| 001651 |
T. Boraud [France] ; E. Bezard [France] ; B. Bioulac [France] ; C. Gross [France] | High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey |
| 001729 |
M.-T. Herrero [Espagne] ; S. J. Augood ; E. C. Hirsch [France] ; F. Javoy-Agid [France] ; M. R. Luquin [Espagne] ; Yves Agid [France] ; J. A. Obeso [Espagne] ; P. C. Emson | Effects of L-DOPA on preproenkephalin and preprotackykinin gene expression in the MPTP-treated monkey striatum |
| 001739 |
B. A. Faucheux [France] ; M. T. Herrero ; J. Villares [France] ; R. Levy [France] ; F. Javoy-Agid [France] ; J. A. Obeso ; J. J. Hauw [France] ; Yves Agid [France] ; E. C. Hirsch [France] | Autoradiographic localization and density of[125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys |
| 001811 |
M. Varastet [France] ; D. Riche [France] ; M. Maziere [France] ; P. Hantraye [France] | Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease |
| 001859 |
I. Marey-Semper [France] ; M. Gelman ; M. Levi-Strauss | The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra |
| 001861 |
P. Hantraye [France] ; M. Varastet [France] ; M. Peschanski [France] ; D. Riche [France] ; P. Cesaro ; J. C. Willer ; M. Maziere [France] | Stable Parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons |
| 001879 |
M. T. Herrero [France] ; I. Perez-Otano ; C. Oset ; A. Kastner [France] ; E. C. Hirsch [France] ; Yves Agid [France] ; M. R. Luquin ; J. A. Obeso ; J. Del Rio | GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys |
| 001888 |
M. T. Herrero [France] ; E. C. Hirsch [France] ; A. Kastner [France] ; M. Ruberg [France] ; M. R. Luquin ; J. Laguna ; F. Javoy-Agid [France] ; J. A. Obeso ; Yves Agid [France] | Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP ? |
| 001890 |
M. T. Herrero [France] ; E. C. Hirsch [France] ; F. Javoy-Agid [France] ; J. A. Obeso ; Yves Agid [France] | Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum |
| 001A11 |
M. Mavridis [France] ; A.-D. Degryse ; A. J. Lategan ; M. R. Marien ; F. C. Colpaert | Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tretrahydropyridine in monkeys : a possible role for the locus coeruleus in the progression of Parkinson's disease |
| 001A54 |
R. Raisman-Vozari ; J.-A. Girault ; S. Moussaoui ; C. Feuerstein ; P. Jenner ; C. D. Marsden ; Yves Agid [France] | Lack of change in triatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man |
| 001A66 |
P. Houze ; O. Chappey ; H. Gallons ; J.-M. Scherrmann | 1-Methyl-4-phenylpyridinium (MMP+) does not exhibit paraquat-like immunoreactivity |
| 001A82 |
B. Cura ; M. Valli | Intérêts du modèle au 1 méthyl 4 phényl 1, 2, 3, 6 tétrahydropyridine (MPTP) dans la physiopathologie de la maladie de Parkinson |
| 001B31 |
D. Scherman ; F. Darchen ; C. Desnos ; J. P. Henry | 1-Methyl-4-phenylpyridinium is a substrate of the vesicular monoamine uptake system of chromaffin granules |
| 001B83 |
P. Hantraye ; C. Loc'H ; U. Tacke ; D. Riche ; O. Stulzaft ; D. Doudet ; B. Guibert ; R. Naquet ; B. Maziere ; M. Maziere | "In vivö visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates |
